LU91073I2 - EMTRICITABINE et ses dérivés pharmaceutiquement acceptables (EMTRIVA) - Google Patents

EMTRICITABINE et ses dérivés pharmaceutiquement acceptables (EMTRIVA)

Info

Publication number
LU91073I2
LU91073I2 LU91073C LU91073C LU91073I2 LU 91073 I2 LU91073 I2 LU 91073I2 LU 91073 C LU91073 C LU 91073C LU 91073 C LU91073 C LU 91073C LU 91073 I2 LU91073 I2 LU 91073I2
Authority
LU
Luxembourg
Prior art keywords
bch
emtriva
emtricitabine
pharmaceutically acceptable
acceptable derivatives
Prior art date
Application number
LU91073C
Other languages
English (en)
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23879071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91073(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Emory filed Critical Univ Emory
Publication of LU91073I2 publication Critical patent/LU91073I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
LU91073C 1990-02-01 1991-01-31 EMTRICITABINE et ses dérivés pharmaceutiquement acceptables (EMTRIVA) LU91073I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/473,318 US5204466A (en) 1990-02-01 1990-02-01 Method and compositions for the synthesis of bch-189 and related compounds
PCT/US1991/000685 WO1991011186A1 (fr) 1990-02-01 1991-01-31 Procede et compositions de synthese de bch-189 et de composes apparentes

Publications (1)

Publication Number Publication Date
LU91073I2 true LU91073I2 (fr) 2004-04-23

Family

ID=23879071

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91073C LU91073I2 (fr) 1990-02-01 1991-01-31 EMTRICITABINE et ses dérivés pharmaceutiquement acceptables (EMTRIVA)

Country Status (22)

Country Link
US (8) US5204466A (fr)
EP (3) EP1772151A3 (fr)
JP (6) JPH07618B2 (fr)
KR (2) KR100188357B1 (fr)
AT (1) ATE170750T1 (fr)
AU (6) AU658136C (fr)
BG (1) BG62236B1 (fr)
CA (3) CA2075189C (fr)
DE (4) DE122004000015I2 (fr)
DK (2) DK0513200T4 (fr)
ES (2) ES2076130T5 (fr)
FI (4) FI114471B (fr)
GR (1) GR950300024T1 (fr)
HK (1) HK1014664A1 (fr)
HU (4) HU227485B1 (fr)
LU (1) LU91073I2 (fr)
MC (1) MC2233A1 (fr)
NL (1) NL300148I2 (fr)
NO (6) NO923014D0 (fr)
RO (1) RO108564B1 (fr)
RU (1) RU2125558C1 (fr)
WO (1) WO1991011186A1 (fr)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US7119202B1 (en) * 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
AU3154993A (en) * 1989-02-08 1994-07-19 Biochem Pharma Inc. Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US20090239887A1 (en) * 1990-02-01 2009-09-24 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
KR100270806B1 (ko) * 1991-03-06 2000-11-01 템블 존 엘 5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2171550C (fr) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides avec activite virale anti-hepatite b
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
DE19514523A1 (de) * 1995-04-12 1996-10-17 Schering Ag Neue Cytosin- und Cytidinderivate
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
EP0938321B1 (fr) 1996-06-25 2004-01-14 Glaxo Group Limited Combinaisons comprenant du vx478, de la zidovudine et du 3tc pouvant etre utilisees dans le traitement du vih
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
CN1196701C (zh) 1997-03-19 2005-04-13 埃莫里大学 1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
EP1754710A3 (fr) 1998-02-25 2007-12-19 Emory University 2'-Fluoronucleosides
KR100954390B1 (ko) 1998-02-25 2010-04-26 에모리 유니버시티 2'-플루오로뉴클레오사이드
ES2255295T3 (es) * 1998-08-10 2006-06-16 Idenix (Cayman) Limited 2'-deoxi-beta-l-nucleosidos para el tratamiento de la hepatitis b.
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
KR100856416B1 (ko) * 1998-08-12 2008-09-04 길리애드 사이언시즈, 인코포레이티드 1,3-옥사티올란 뉴클레오시드의 제조 방법
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
CN1666742A (zh) 1998-11-02 2005-09-14 三角药物公司 对乙型肝炎病毒的联合治疗
KR100618028B1 (ko) 1998-11-05 2006-08-30 쌍트르 나쉬오날 드 라 르쉐르스 쉬앙티피끄 항-ｂ형 간염 활성을 가진 뉴클레오시드
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
OA11741A (en) 1998-12-23 2005-05-13 Iaf Biochem Int Antiviral nucleoside analogues.
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
CN1919858A (zh) * 1999-11-12 2007-02-28 法玛赛特有限公司 2＇－脱氧－l－核苷的合成
EP1634888A3 (fr) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthèse de 2'-désoxy-L-nucléosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (fr) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones utiles pour la preparation d'analogues de nucleosides antiviraux
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (fr) * 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Procédés et compositions de traitement des flavivirus et des pestivirus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CN1446225A (zh) * 2000-08-09 2003-10-01 可隆株式会社 5′－脱氧－n－(取代氧羰基)－5－氟胞嘧啶及其衍生物、制备方法,和包括该物质作为活性成分的抗癌组合物
US20030166606A1 (en) * 2000-08-09 2003-09-04 Kwan-Hee Kim 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
DE10104231A1 (de) * 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
KR101015510B1 (ko) * 2001-03-01 2011-02-16 길리애드 사이언시즈, 인코포레이티드 시스-ｆｔｃ의 다형 및 기타 결정형
CA2380804A1 (fr) * 2001-05-01 2002-11-01 Mitsui Chemicals, Inc. Methode pour la production de composes nucleosidiques a base de cytosine
CA2351049C (fr) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Procede pour separer des nucleosides cis-1,3-oxathiolaniques recherches de leurs isomeres trans non desires
ITMI20012317A1 (it) * 2001-11-06 2003-05-06 Recordati Ind Chimica E Farma Processo diastereoselettivo per la preparazione del'agente antivirale4-amino-1-(2r-idrossimetil-/1,3/ossatiolan-5s-i1)-1h-pirimidin-2-one
WO2003051298A2 (fr) * 2001-12-14 2003-06-26 Pharmasset Ltd. Preparation d'intermediaires utiles dans la synthese de nucleosides antiviraux
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
MXPA04009986A (es) * 2002-04-12 2005-08-16 Achillion Pharmaceuticals Inc Metodo para sintetizar beta-l-5-fluoro-2¦,3¦-didesoxi-2¦,3¦-dideshidrocitidina (¦-l-fd4c).
MXPA04012802A (es) * 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
CN101172993A (zh) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
ES2360096T3 (es) 2002-08-06 2011-05-31 Pharmasset, Inc. Procedimientos de preparación de nucleosidos de 1,3-dioxolano.
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
BR0314259A (pt) * 2002-09-13 2005-07-26 Idenix Cayman Ltd ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas
MXPA05005192A (es) * 2002-11-15 2005-09-08 Idenix Cayman Ltd Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
BR0317113A (pt) * 2002-12-09 2005-10-25 Univ Georgia Res Found Timina dioxolano e combinações para uso contra cepas resistentes a 3tc/azt de hiv
CA2509687C (fr) * 2002-12-12 2012-08-14 Idenix (Cayman) Limited Procede de production de nucleosides ramifies en position 2'
AU2004206821C1 (en) * 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
RU2361875C2 (ru) * 2003-06-30 2009-07-20 Айденикс (Кайман) Лимитед СИНТЕЗ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
US7785839B2 (en) 2004-02-03 2010-08-31 Emory University Methods to manufacture 1,3-dioxolane nucleosides
EP2258376B1 (fr) 2004-07-27 2019-02-27 Gilead Sciences, Inc. Analogues phosphonates de composés inhibiteurs du VIH
JP4058057B2 (ja) * 2005-04-26 2008-03-05 株式会社東芝 日中機械翻訳装置、日中機械翻訳方法および日中機械翻訳プログラム
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EP1940781A1 (fr) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phénylacétamides en tant qu'inhibiteurs de nnrt
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
ES2422290T3 (es) * 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
ES2340885T3 (es) * 2006-01-17 2010-06-10 N.V. Organon Hidrolisis enzimatica selectiva de esteres terc-butilicos c terminal de peptidos.
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
ES2357159T3 (es) * 2006-04-18 2011-04-19 Lupin Ltd. Forma cristalina novedosa de lamivudina.
ES2546378T3 (es) 2006-07-07 2015-09-23 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de agentes terapéuticos
WO2008071587A2 (fr) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Inhibiteurs non nucléosidiques de la transcriptase inverse
EA019893B1 (ru) 2007-02-23 2014-07-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и способ лечения вич-инфекции
CN101307048B (zh) * 2007-05-18 2011-03-23 上海迪赛诺医药发展有限公司 立体选择性制备拉米夫定的方法
PL2159224T3 (pl) 2007-06-18 2012-12-31 Ruyuan Wei Xiang Tech Co Ltd Tiazolilohydropirymidyny podstawione bromofenylem
BRPI0813709A2 (pt) 2007-07-09 2015-01-06 Eastern Virginia Med School Derivados de nucleosídeo substituído com propriedades antiviral e antimicrobiana
WO2009052050A1 (fr) * 2007-10-15 2009-04-23 Pharmasset, Inc. Phosphoramidates de dioxolane-thymine comme agents anti-vih
BRPI0820224A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
SI2225232T1 (sl) * 2007-11-29 2012-12-31 Ranbaxy Laboratories Limited Postopek za pripravo substituiranih 1,3-oksatiolanov
US8252919B2 (en) 2008-02-29 2012-08-28 Kaneka Corporation 2′-hydroxy-protected ribonucleoside derivative and production method thereof
WO2010055526A1 (fr) 2008-11-12 2010-05-20 Lupin Limited Nouveau polymorphe de l'emtricitabine et procédé pour sa préparation
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
US20110282046A1 (en) 2009-01-19 2011-11-17 Rama Shankar Process for preparation of cis-nucleoside derivative
KR101474570B1 (ko) 2009-04-13 2014-12-19 주식회사 대희화학 라미부딘의 신규한 중간체 및 이의 제조방법
DK2435825T3 (en) 2009-05-27 2015-10-19 Biotempus Ltd Modes for medical care
EP2454244B1 (fr) 2009-07-15 2013-06-26 Lupin Limited Procédé perfectionné de préparation d'efavirenz
WO2011095987A1 (fr) 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Noveau procede de preparation de derive de cis-nucleoside
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2011141805A2 (fr) 2010-05-14 2011-11-17 Lupin Limited Procédé de production amélioré de lamivudine
WO2013021290A1 (fr) 2011-08-05 2013-02-14 Lupin Limited Procédé stéréosélectif de préparation de nucléosides 1,3-oxathiolane
CN102584800A (zh) * 2011-12-16 2012-07-18 四川大学 手性吲哚酮和当归内酯骨架化合物及不对称合成
JP2015520144A (ja) 2012-05-11 2015-07-16 アクロン・モレキュールズ・アクチェンゲゼルシャフトＡｋｒｏｎ Ｍｏｌｅｃｕｌｅｓ Ａｇ 疼痛の治療のための化合物の使用
JP2016506371A (ja) * 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヌクレオシドプロドラッグを調製する方法
MD4736C1 (ro) 2012-12-21 2021-07-31 Gilead Sciences, Inc. Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
NO2865735T3 (fr) 2013-07-12 2018-07-21
HUE037347T2 (hu) 2013-07-12 2018-08-28 Gilead Sciences Inc Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
EP3038607A2 (fr) 2013-08-29 2016-07-06 Teva Pharmaceutical Industries Ltd. Forme pharmaceutique unitaire comprenant de l'emtricitabine, du ténofovir, du darunavir et du ritonavir et un comprimé monolithique comprenant du darunavir et du ritonavir
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (fr) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016001907A1 (fr) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CA2954056C (fr) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulateurs de recepteurs de type toll pour le traitement du vih
WO2016033164A1 (fr) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Dérivés de nucléosides et de nucléotides
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
PL3277691T3 (pl) 2015-04-02 2019-07-31 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
JP2018527366A (ja) 2015-09-15 2018-09-20 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター
GB201610327D0 (en) * 2016-06-14 2016-07-27 Univ Nelson Mandela Metropolitan Process for producing Lamivudine and Entricitabine
US11498933B2 (en) 2017-03-31 2022-11-15 The John Hopkins University Prodrug compositions
EP3737676B1 (fr) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Composés acétal et leurs utilisations thérapeutiques

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5259171A (en) * 1975-11-10 1977-05-16 Asahi Chem Ind Co Ltd Preparation of uracil derivatives
JPS6045196B2 (ja) * 1976-08-09 1985-10-08 株式会社興人 １−（２−テトラヒドロフリル）ウラシル類の製造方法
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
JPS5839672A (ja) * 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
WO1985000608A1 (fr) * 1983-07-20 1985-02-14 Teijin Limited Agent antineoplastique
DE3534979A1 (de) * 1985-07-25 1987-01-29 Licentia Gmbh Netzgeraet
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
GB2181128A (en) * 1985-09-17 1987-04-15 Wellcome Found 3'-azidonucleosides
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
NZ223990A (en) * 1987-03-24 1990-08-28 Nycomed As Acylated 2',3'-dideoxynucleosides and pharmaceutical compositions
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5011774A (en) * 1987-07-17 1991-04-30 Bristol-Myers Squibb Co. Dideoxyinosine by enzymatic deamination of dideoxyadenosine
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
CA1318627C (fr) * 1988-07-14 1993-06-01 Jeffrey M. Howell Procede de resolution enzymatique
US5106750A (en) * 1988-08-30 1992-04-21 G. D. Searle & Co. Enantio- and regioselective synthesis of organic compounds using enol esters as irreversible transacylation reagents
JPH0269469A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ジヒドロフラン誘導体及びその製法
JPH0269476A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ピリミジン誘導体の製法
GB8822546D0 (en) * 1988-09-26 1988-11-02 Wellcome Found Antiviral combinations
EP0375329B1 (fr) * 1988-12-19 1995-05-31 The Wellcome Foundation Limited Dérivés antiviraux de pyrimidine et de purine, leur procédé de préparation et compositions pharmaceutiques les contenant
AU3154993A (en) * 1989-02-08 1994-07-19 Biochem Pharma Inc. Process for preparing substituted 1,3-oxathiolanes with antiviral properties
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
CA2023856A1 (fr) * 1989-09-26 1991-03-27 Jeffrey M. Howell Procede de resolution enzymatique
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US6642245B1 (en) * 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
WO1992010496A1 (fr) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. NUCLEOSIDES DE β-L-(-)-1,3-OXATHIOLANE ENANTIOMERIQUEMENT PURS
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
KR100270806B1 (ko) * 1991-03-06 2000-11-01 템블 존 엘 5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제
WO1992018517A1 (fr) * 1991-04-17 1992-10-29 Yale University Procede de traitement ou de prevention du virus de l'hepatite b
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
SE510803C2 (sv) * 1994-12-13 1999-06-28 Volvo Ab Tryckmediepåverkad manöveranordning
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer

Also Published As

Publication number Publication date
ES2279559T3 (es) 2007-08-16
FI116222B (fi) 2005-10-14
DE122004000015I1 (de) 2004-08-12
DE69130166D1 (de) 1998-10-15
AU7300491A (en) 1991-08-21
MC2233A1 (fr) 1993-02-23
NO923014L (no) 1992-07-30
DE69133556D1 (de) 2007-03-08
DK0513200T4 (da) 2004-07-05
ATE170750T1 (de) 1998-09-15
HU9202496D0 (en) 1992-12-28
HU211300A9 (en) 1995-11-28
NO20083728L (no) 1992-07-30
WO1991011186A1 (fr) 1991-08-08
NO313048B1 (no) 2002-08-05
KR920703582A (ko) 1992-12-18
JP3844978B2 (ja) 2006-11-15
GR950300024T1 (en) 1995-06-30
EP0513200A4 (en) 1993-04-07
NO324979B1 (no) 2008-01-14
ES2076130T5 (es) 2004-12-16
FI20060622A (fi) 2006-06-27
JP3530150B2 (ja) 2004-05-24
JP2002012591A (ja) 2002-01-15
EP1772151A3 (fr) 2007-06-13
AU2002300661B2 (en) 2006-06-08
EP0513200B2 (fr) 2004-04-28
KR100188357B1 (ko) 1999-06-01
CA2075189A1 (fr) 1991-08-02
KR100381705B1 (ko) 2003-04-26
US5814639A (en) 1998-09-29
US5210085A (en) 1993-05-11
ES2076130T3 (es) 1999-03-01
FI923446A0 (fi) 1992-07-30
NO970386L (no) 1992-07-30
FI114471B (fi) 2004-10-29
US20050004148A1 (en) 2005-01-06
DE122004000015I2 (de) 2004-11-18
NO970385D0 (no) 1997-01-29
NO2008011I1 (no) 2008-07-28
HUT62566A (en) 1993-05-28
NL300148I2 (nl) 2004-11-01
US6153751A (en) 2000-11-28
FI20030933A (fi) 2003-06-24
AU698859B2 (en) 1998-11-12
NO2008011I2 (no) 2010-10-18
US6114343A (en) 2000-09-05
AU658136C (en) 2003-06-12
JPH05505794A (ja) 1993-08-26
RO108564B1 (ro) 1994-06-30
JPH07618B2 (ja) 1995-01-11
DE69130166T2 (de) 1999-04-08
DK0513200T3 (da) 1999-05-25
US5914400A (en) 1999-06-22
JP2005053893A (ja) 2005-03-03
AU4031995A (en) 1996-04-26
JP4496377B2 (ja) 2010-07-07
AU4474599A (en) 1999-11-11
HK1014664A1 (en) 1999-09-30
NL300148I1 (nl) 2004-07-01
CA2678778A1 (fr) 1991-08-08
RU2125558C1 (ru) 1999-01-27
AU658136B2 (en) 1995-04-06
FI923446A (fi) 1992-07-30
EP0513200B1 (fr) 1998-09-09
NO923014D0 (no) 1992-07-30
AU2006207874A1 (en) 2006-09-28
NO20065640L (no) 1992-07-30
CA2075189C (fr) 2004-11-30
JP2006141408A (ja) 2006-06-08
HU227485B1 (en) 2011-07-28
NO970385L (no) 1992-07-30
CA2481078A1 (fr) 1991-08-08
CA2481078C (fr) 2009-12-15
NO970386D0 (no) 1997-01-29
FI121069B (fi) 2010-06-30
JP2001352997A (ja) 2001-12-25
JP2001019690A (ja) 2001-01-23
EP0872237A1 (fr) 1998-10-21
FI20050672A (fi) 2005-06-22
EP0513200A1 (fr) 1992-11-19
DE69130166T3 (de) 2005-04-14
EP1772151A2 (fr) 2007-04-11
AU698859C (en) 2003-01-30
US5204466A (en) 1993-04-20
DE69133556T2 (de) 2007-08-16
DK0872237T3 (da) 2007-04-23
US5539116A (en) 1996-07-23
AU2010201878A1 (en) 2010-05-27
JP4108645B2 (ja) 2008-06-25
ES2076130T1 (es) 1995-11-01
AU2006207874B2 (en) 2010-02-11
BG62236B1 (bg) 1999-06-30
NO326249B1 (no) 2008-10-27
EP0872237B1 (fr) 2007-01-17
DE513200T1 (de) 1995-07-13

Similar Documents

Publication Publication Date Title
LU91073I2 (fr) EMTRICITABINE et ses dérivés pharmaceutiquement acceptables (EMTRIVA)
DE69331753D1 (de) 5-Halo-5-Deoxy-Sorbopyranose-Verbindungen